Clinical trials tracking nonalcoholic fatty liver disease: Noninvasive measures
10.3969/j.issn.1001-5256.2018.12.003
- VernacularTitle:跟踪非酒精性脂肪性肝病的临床试验-无创指标评价
- Author:
Huanjia QU
1
;
Junping SHI
Author Information
1. Department of Infectious Disease, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
- Publication Type:Research Article
- Keywords:
non-alcoholic fatty liver disease;
clinical trial;
noninvasive makers
- From:
Journal of Clinical Hepatology
2018;34(12):2501-2504
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD) has become one of the research hotspots in the field of liver disease. However, so far, no drugs have been approved by the U.S. Food and Drug Administration for the treatment of nonalcoholic steatohepatitis, which brings opportunities and challenges to the clinical trials on the treatment of NAFLD. Liver histology is currently considered a reliable surrogate endpoint for tracking the progression of NAFLD, but its invasiveness has limited the development of drugs for the treatment of NAFLD. In recent years, some noninvasive measurement methods have gradually been used as secondary or exploratory endpoints in existing clinical trials.
